Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 3, 2017, Pages 349-359

  Berden, Floor A C ^a   Aaldering, Bryan R R Z ^a   Groenewoud, Hans ^a   IntHout, Joanna ^a   Kievit, Wietske ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Comparative Effectiveness; Mixed Treatment Comparison; NS5A Inhibitor; NS5B Inhibitor

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; LEDIPASVIR; OMBITASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TELAPREVIR; VELPATASVIR;

ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION; CLASSIFICATION; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; NETWORK META-ANALYSIS; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

EID: 85013216647     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.10.034     Document Type: Article

References (49)

1. 1 Lauer, G.M., Walker, B.D., Hepatitis C virus infection. N Engl J Med 345 (2001), 41–52.
2. 2 Alqahtani, S.A., Afdhal, N., Zeuzem, S., et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 62 (2015), 25–30.
3. 3 Suwanthawornkul, T., Anothaisintawee, T., Sobhonslidsuk, A., et al. Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C genotype 1: a systematic review and network meta-analysis. PLoS One, 10, 2015, e0145953.
4. 4 Majumdar, A., Kitson, M.T., Roberts, S.K., Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 43 (2016), 1276–1292.
5. 5 US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment: guidance for industry (revision 2, draft). 2016.
6. 6 Hutton, B., Salanti, G., Caldwell, D.M., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162 (2015), 777–784.
7. 7 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 The Cochrane Collaboration. Available from: www.handbookcochrane.org. Accessed: 2016.
8. 8 Goring, S.M., Gustafson, P., Liu, Y., et al. Disconnected by design: analytic approach in treatment networks having no common comparator. Research Synthesis Methods 7 (2016), 420–432.
9. 9 AASLD/IDSA. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Available: www.hcvguidelines.org. Accessed: July 6, 2016.
10. 10 EASL, EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
11. 11 WHO. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: updated version. World Health Organization, Geneva: 2016.
12. 12 Salanti, G., Ades, A.E., Ioannidis, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64 (2011), 163–171.
13. 13 Lunn, D.J., Thomas, A., Best, N., et al. WinBUGS – A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10 (2000), 325–337.
14. 14 R-Development Core Team. R: a language and environment for statistical computing. 2011, R Foundation for Statistical Computing, Vienna, Austria.
15. 15 Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
16. 16 Dore, G.J., Lawitz, E., Hezode, C., et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 148 (2015), 355–366.e1.
17. 17 Everson, G.T., Towner, W.J., Davis, M.N., et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med 163 (2015), 818–826.
18. 18 Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
19. 19 Foster, G.R., Hezode, C., Bronowicki, J.P., et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141 (2011), 881–889.e1.
20. 20 Foster, G.R., Irving, W.L., Cheung, M.C., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
21. 21 Foster, G.R., Pianko, S., Brown, A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis c virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
22. 22 Gane, E.J., Hyland, R.H., An, D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461.e1.
23. 23 Gane, E.J., Stedman, C.A., Hyland, R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368 (2013), 34–44.
24. 24 Hezode, C., de Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology, 62, 2015 314a-a.
25. 25 Jacobson, I.M., Gordon, S., Kowdley, K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 (2013), 1867–1877.
26. 26 Lawitz, E., Mangia, A., Wyles, D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
27. 27 Lawitz, E., Poordad, F., Brainard, D.M., et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 61 (2015), 769–775.
28. 28 Lawitz, E., Sullivan, G., Rodriguez-Torres, M., et al. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 70 (2015), 197–205.
29. 29 Leroy, V., Angus, P., Bronowicki, J.P., et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63 (2016), 1430–1441.
30. 30 Lin, O.N., Nguyen, N., Chang, C.Y., et al. Safety and effectiveness of sofosbuvir (SOF) combined with ribavirin (RBV) for the treatment of genotype 2 and 3 chronic hepatitis C infection (HCV-2 and HCV-3). Gastroenterology, 148(4 SUPPL 1), 2015, S1092.
31. 31 Molina, J.M., Orkin, C., Iser, D.M., et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 385 (2015), 1098–1106.
32. 32 Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
33. 33 Pianko, S., Flamm, S.L., Shiffman, M.L., et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 163 (2015), 809–817.
34. 34 Poordad, F., Schiff, E.R., Vierling, J.M., et al. Daclatasvir, sofosbuvir, and ribavirin combination for Hcv patients with advanced cirrhosis or posttransplant recurrence: phase 3 Ally-1 study. J Hepatol 62:SUPPL 2 (2015), S261–S262.
35. 35 Shah, S., Acharya, S.K., Mehta, R., et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV infection in India. Hepatol Int, 10(1 SUPPL 1), 2016, S15.
36. 36 Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370 (2014), 211–221.
37. 37 Sulkowski, M.S., Naggie, S., Lalezari, J., et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312 (2014), 353–361.
38. 38 Welzel, T.M., Petersen, J., Ferenci, P., et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program. Hepatology, 62, 2015 225a-6a.
39. 39 Wyles, D.L., Ruane, P.J., Sulkowski, M.S., et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373 (2015), 714–725.
40. 40 Zeuzem, S., Dusheiko, G.M., Salupere, R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
41. 41 Hezode, C., Bronowicki, J.P., Ideal oral combinations to eradicate HCV: the role of ribavirin. J Hepatol 64 (2016), 215–225.
42. 42 Jansen, J.P., Fleurence, R., Devine, B., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14 (2011), 417–428.
43. 43 Druyts, E., Lorenzi, M., Toor, K., et al. Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. QJM 108 (2015), 299–306.
44. 44 Kieran, J., Schmitz, S., O'Leary, A., et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 56 (2013), 228–235.
45. 45 Singh, S., Murad, M.H., Chandar, A.K., et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 149 (2015), 958–970 e12.
46. 46 Singh, S., Garg, S.K., Pardi, D.S., et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology 148 (2015), 64–76 e2 quiz e14.
47. 47 Skapinakis, P., Caldwell, D.M., Hollingworth, W., et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 3 (2016), 730–739.
48. 48 Marcellin, P., Cheinquer, H., Curescu, M., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 56 (2012), 2039–2050.
49. 49 Cipriani, A., Higgins, J.P., Geddes, J.R., et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159 (2013), 130–137.